Relay Therapeutics Stock Net Asset
| RLAY Stock | USD 3.25 0.04 1.22% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Relay Therapeutics' long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Relay Therapeutics Company Net Asset Analysis
Relay Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Relay Therapeutics Net Asset | 871.3 M |
Most of Relay Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Relay Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Relay Therapeutics has a Net Asset of 871.3 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Relay Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Relay Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Relay Therapeutics could also be used in its relative valuation, which is a method of valuing Relay Therapeutics by comparing valuation metrics of similar companies.Relay Therapeutics is currently under evaluation in net asset category among its peers.
Relay Fundamentals
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (38.54) % | ||||
| Current Valuation | (181.87 M) | ||||
| Shares Outstanding | 170.49 M | ||||
| Shares Owned By Insiders | 1.80 % | ||||
| Shares Owned By Institutions | 98.20 % | ||||
| Number Of Shares Shorted | 18.36 M | ||||
| Price To Book | 0.72 X | ||||
| Price To Sales | 55.37 X | ||||
| Revenue | 10.01 M | ||||
| Gross Profit | (305.43 M) | ||||
| EBITDA | (372.47 M) | ||||
| Net Income | (337.71 M) | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 8.72 X | ||||
| Total Debt | 48.5 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 15.22 X | ||||
| Book Value Per Share | 4.64 X | ||||
| Cash Flow From Operations | (249.11 M) | ||||
| Short Ratio | 6.02 X | ||||
| Earnings Per Share | (2.36) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 17.36 | ||||
| Number Of Employees | 261 | ||||
| Beta | 1.7 | ||||
| Market Capitalization | 554.09 M | ||||
| Total Asset | 871.3 M | ||||
| Retained Earnings | (1.74 B) | ||||
| Working Capital | 758.48 M | ||||
| Net Asset | 871.3 M |
About Relay Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Relay Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relay Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relay Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.